⁍ The announcement comes one day after Johnson & Johnson said it was forced to pause a large high-profile trial of its experimental coronavirus vaccine.

---

⁍ It is not uncommon to pause drug trials to investigate safety concerns.

---

⁍ Lilly began its ACTIV-3 trial in August and is aiming to recruit 10,000 patients primarily in the United States.

---

– A government-sponsored clinical trial of an antibody treatment similar to one given to President Trump has been halted because of a safety concern. Eli Lilly and Co. said Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by US President Trump has been paused because of a safety concern, Reuters reports. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc. REGN.O that he received for his COVID-19, as tantamount to a cure in a video he posted last week. The announcement comes one day after Johnson & Johnson said it was forced to pause a large high-profile trial of its experimental coronavirus vaccine because a volunteer fell ill. J&J said it does not yet know if that person was given the vaccine or a placebo. AstraZeneca Plc’s AZN.L US trial for its experimental COVID-19 vaccine has also been on hold for over a month after a volunteer in its UK study fell ill. Trials of that vaccine resumed in other regions after a brief halt. Lilly said earlier this month it was applying for emergency use authorization (EUA) for the antibody drug, LY-CoV555, for patients with mild to moderate COVID-19 based on data from another clinical trial. It is not uncommon to pause drug trials to investigate safety concerns, and such actions do not necessarily indicate a serious problem. Because of the urgent need for drugs and vaccines to tackle a pandemic that has claimed more than 1 million lives worldwide—and the speed with which they are being developed.